Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de mantenimiento de primera línea con Lenalidomida (Revlimid®) en pacientes con linfoma de células del manto. A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, FIRST LINE MAINTENANCE STUDY OF LENALIDOMIDE (REVLIMID®) IN PATIENTS WITH MANTLE-CELL LYMPHOMA Evaluar la eficacia de la lenalidomida como tratamiento de mantenimiento después de la finalización de la quimioterapia combinada de primera línea en pacientes con linfoma de células del manto (LCM) q...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) - To continue to provide chlorambucil to subjects randomized to the chlorambucil arm and aged ≥ 65 and < 81 years of age up to 13 cycles (approximately 12 months), at the discretion of the Investi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

STUDIO DI FASE III, MULTICENTRICO, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO, A GRUPPI PARALLELI PER VALUTARE L EFFICACIA E LA SICUREZZA DI LENALIDOMIDE (REVLIMID) VERSO PLACEBO IN SOGGETTI AFFETTI DA ANEMIA TRASFUSIONE-DIPENDENTE DOVUTA A SINDROMI MIELODISPLASTICHE A RISCHIO BASSO O INTERMEDIO-1 SECONDO I CRITERI IPSS, SENZA ANOMALIA CITOGENETICA DA DELEZIONE 5Q[31] E NON RESPONSIVI O REFRATTARI AI FATTORI DI CRESCITA ERITROPOIETICI To compare the efficacy of lenalidomide versus placebo in subjects with red blood cell (RBC) transfusiondependent low or Int-1 risk MDS associated with any karyotype except deletion 5q[31] and unresp...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Study of CC-10004 in Subjects with Moderate-to-severe Plaque-Type Psoriasis To compare the clinical efficacy of 2 oral (PO) doses of CC-10004 (20 mg once daily (QD) and 20 mg twice daily (BID)) with placebo when taken for 12 weeks in subjects with moderate-to-severe plaque-ty...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to compare the safety and effectiveness of Abraxane versus dacarbazine, in the treatment of advanced stage melanoma that has spread to other parts of the body (metastatic malignant melanoma) The primary objective of this study is to compare the following regimens with respect to antitumor activity in patients who are previously untreated with cytotoxic chemotherapy for metastatic malignan...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of lenalidomide plus R-CHOP chemotherapy versus placebo plus R-CHOP chemotherapy in untreated diffuse large B-cell lymphoma To compare the efficacy of lenalidomide, rituximab, cyclophosphamide, doxorubicin,vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab,cyclophosphamide, doxorubicin, vincristi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT OR IN COMBINATION WITH PREDNISONE TO STUDY FURTHER IN SUBJECTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIA •To select a treatment regimen of CC-4047 either as single-agent or in combination with prednisone to study further in subjects with myelofibrosis with myeloid metaplasia.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A clinical trial to evaluate if CC-486 plus pembrolizumab works and is safe in patients with advanced or metastatic non-small cell lung cancer who have previously received platinum containing treatment • To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus placebo based on PFS as measured using RECIST 1.1 criteria

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Two parts study, the first part is to determine the dose of azacitidine and the second part is to evaluate the effect of azacitidine compared to no treatment, in children and young adults following a molecular relapse of acute myeloid leukemia after the first complete remission Safety Run-in Part -To establish a safe and tolerable dose of azacitidine to be used in the randomized part of the study. Randomized Part -To evaluate the effect of azacitidine treatment in AML subj...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized trial of maintenance treatment between Lenalidomide and Placebo administred after a combination of Melphalan, Prednisone and Bortezomib as 1st intention in subjects diagnosed with multiple myeloma. Tυχαιοποιημένη κλινική μελέτη σύγκρισης της θεραπείας συντήρησης με λεναλιδομίδη έναντι placebo, χορηγουμένων μετά από θεραπεία εφόδου (1ης γραμμής) με συνδυασμό Μελφαλάνης, Πρεδνιζόνης και Βορτεζομίμπης σε ασθενείς διαγνωσμένους με πολλαπλό μυέλωμα To compare the progression free survival (PFS) of maintenance therapy with lenalidomide versus placebo after Melphalan Prednisone Velcade® (MPV) induction therapy in subjects with NDMM who are either ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune